Literature DB >> 33503182

miRNA-195 expression in the tumor tissues of female Brazilian breast cancer patients with operable disease.

Alexandre Cesar Vieira de Sales1,2, Isaura Isabelle Fonseca Gomes da Silva1, Matheus Carvalho Brito Leite1, Leandro de Lima Coutinho1, Renata Bezerra de Albuquerque Cavalcante Reis1, Danyelly Bruneska Gondin Martins1, José Luiz de Lima Filho1, Fabrício Oliveira Souto1,2.   

Abstract

OBJECTIVE: This study aimed to assess miRNA-195 expression in the tumor tissues from a cohort of Brazilian female breast cancer patients undergoing neoadjuvant chemotherapy (NAC) and evaluate its correlation with various clinicopathological markers.
METHODS: Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to evaluate the miRNA-195 expression in tumor tissues from a cohort of female breast cancer patients undergoing NAC. This expression was then correlated with the occurrence of several distinct breast cancer molecular subtypes and other clinicopathological variables.
RESULTS: A total of 55 patients were included in this study, 28 (50.9%) of whom were treated using NAC. Tumor miRNA-195 expression was suppressed in breast cancer patients, regardless of their exposure to systemic treatments, histological grade, size, nodal status, and tumor-node-metastasis (TNM) staging. This was more pronounced in luminal and triple-negative patients, and patient's response to NAC was correlated with an increase in miRNA-195 expression.
CONCLUSION: miRNA-195 is downregulated in the tumor tissues of Brazilian breast cancer patients regardless of NAC exposure; this reinforces its role as a tumor suppressor and a potential biomarker for chemotherapy response.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33503182      PMCID: PMC7798133          DOI: 10.6061/clinics/2021/e2142

Source DB:  PubMed          Journal:  Clinics (Sao Paulo)        ISSN: 1807-5932            Impact factor:   2.365


  31 in total

Review 1.  MicroRNAs in cancer: biomarkers, functions and therapy.

Authors:  Josie Hayes; Pier Paolo Peruzzi; Sean Lawler
Journal:  Trends Mol Med       Date:  2014-07-12       Impact factor: 11.951

2.  Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease.

Authors:  Helen M Heneghan; Nicola Miller; Ronan Kelly; John Newell; Michael J Kerin
Journal:  Oncologist       Date:  2010-06-24

3.  Circulating miR-195 as a Therapeutic Biomarker in Turkish Breast Cancer Patients.

Authors:  Gulsah Cecene; Secil Ak; Gamze Guney Eskiler; Elif Demirdogen; Elif Erturk; Sehsuvar Gokgoz; Volkan Polatkan; Unal Egeli; Berrin Tunca; Gulcin Tezcan; Ugur Topal; Sahsine Tolunay; Ismet Tasdelen
Journal:  Asian Pac J Cancer Prev       Date:  2016

Review 4.  MicroRNAs in body fluids--the mix of hormones and biomarkers.

Authors:  Maria Angelica Cortez; Carlos Bueso-Ramos; Jana Ferdin; Gabriel Lopez-Berestein; Anil K Sood; George A Calin
Journal:  Nat Rev Clin Oncol       Date:  2011-06-07       Impact factor: 66.675

Review 5.  Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis.

Authors:  Heidi D Nelson; Bernadette Zakher; Amy Cantor; Rongwei Fu; Jessica Griffin; Ellen S O'Meara; Diana S M Buist; Karla Kerlikowske; Nicolien T van Ravesteyn; Amy Trentham-Dietz; Jeanne S Mandelblatt; Diana L Miglioretti
Journal:  Ann Intern Med       Date:  2012-05-01       Impact factor: 25.391

6.  Circulating microRNAs as novel minimally invasive biomarkers for breast cancer.

Authors:  Helen M Heneghan; Nicola Miller; Aoife J Lowery; Karl J Sweeney; John Newell; Michael J Kerin
Journal:  Ann Surg       Date:  2010-03       Impact factor: 12.969

7.  Prevalence of molecular subtypes of invasive breast cancer: A retrospective study.

Authors:  Nikhilesh Kumar; Preeti Patni; A Agarwal; M A Khan; Nidhi Parashar
Journal:  Med J Armed Forces India       Date:  2015-06-17

8.  Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

Authors:  A Goldhirsch; W C Wood; A S Coates; R D Gelber; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2011-06-27       Impact factor: 32.976

9.  Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.

Authors:  Yao-Yin Chang; Wen-Hung Kuo; Jui-Hui Hung; Chien-Yueh Lee; Yung-Hua Lee; Ya-Chu Chang; Wen-Chun Lin; Cheng-Ying Shen; Chiun-Sheng Huang; Fon-Jou Hsieh; Liang-Chuan Lai; Mong-Hsun Tsai; King-Jen Chang; Eric Y Chuang
Journal:  Mol Cancer       Date:  2015-02-10       Impact factor: 27.401

Review 10.  MicroRNA-195: a review of its role in cancers.

Authors:  Wanpeng Yu; Xiao Liang; Xiangdong Li; Yuan Zhang; Zhenqing Sun; Ying Liu; Jianxun Wang
Journal:  Onco Targets Ther       Date:  2018-10-17       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.